Taken together, no matter patients chose to switch to other chemotherapy or anti-angiogenesis therapy beyond first progression, the addition of PD-1/PD-L1 inhibitors could benefit SCLC patients. This evidence concerns the gene CD274 and small cell lung carcinoma.